ANNX vs ELDN
ANNX: Annexon is a clinical-stage biotechnology company developing C1q-inhibitor therapies to treat neurodegenerative and autoimmune diseases driven by the classical complement pathway. ELDN: Eledon Pharmaceuticals is a clinical-stage biotech developing immune-modulating therapies for autoimmune diseases and organ transplantation.
Side-by-side fundamentals
| Metric | ANNX | ELDN | Edge |
|---|---|---|---|
| Price as of 2026-08-10 close | $5.39 | $3.68 | |
| Market cap as of 2026-08-11 | $883M | $284M | |
| PEG as of 2026-08-11 | -1.19 | n/a | |
| ROE as of 2026-08-11 | -101.2% | -72.0% | ELDN higher |
| ROA as of 2026-08-11 | -76.0% | -52.9% | ELDN higher |
| Debt / equity as of 2026-08-11 | 0.00 | 0.00 | Tie |
| Dividend streak (yrs) SEC XBRL | 0 | n/a | |
| Beta as of 2026-08-11 | 1.29 | 0.89 | |
| 1-year return as of 2026-08-10 close | +128.4% | +35.5% | ANNX higher |
Fundamentals: market data, as of 2026-08-11. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-10.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.